Lichenoid Eruption Induced by Low Dose Captopril

S. S. WONG, C. C. LONG and P. J. A. HOLT
Department of Dermatology, University Hospital of Wales, Cardiff, Wales, UK

A patient with congestive cardiac failure developed a rash following captopril treatment. The clinical and histological features were consistent with a lichenoid eruption. The rash spontaneously resolved without any treatment three months after captopril was discontinued. Key words: A.C.E. inhibitors; Sulphydryl group; Papules.

(Accepted December 16, 1991.)


C. C. Long, Department of Dermatology, University Hospital of Wales, Cardiff, CF4 4XW, Wales, United Kingdom.

Rashes occurring during the first few weeks of treatment have been the commonest of the side effects reported with captopril. Lichenoid eruptions produced by captopril are uncommon. We report the first case of a lichenoid eruption induced by low dose captopril.

CASE REPORT

An 83-year-old woman with long-standing aortic stenosis presented in March 1991 with left ventricular failure and atrial fibrillation. She was treated initially with diuretics and digoxin. Captopril 6.25 mg three times daily was added to her treatment one week later to further control her heart failure. She improved significantly and was discharged on captopril 12.5 mg twice daily. She presented in June 1991 with an itchy rash affecting her arms, upper chest, back and the sides of the neck. Captopril was thought to be the cause of the rash, and she was admitted to hospital for monitoring of her heart failure whilst the drug was withdrawn.

Examination at this time revealed multiple violaceous papules and plaques with some scaling on her arms, upper chest, back and neck. There were no blisters or mucosal lesions. A skin biopsy from a papule on the upper chest showed superficial perivascular and interface chronic inflammation with focal disruption of the basal layer with epidermal atrophy. There was patchy hypergranulosis, and necrotic keratinocytes were seen within the epidermis and in the basal layer (Fig. 1). Direct immunofluorescence showed IgG and C3 intrapidermal cytoid bodies with a fibrin band along the dermo-epidermal junction. The rash began to fade within 48 h of stopping the drug. She developed heart failure one week after drug withdrawal and enalapril 5 mg daily was substituted for captopril. There has been no exacerbation or recurrence of the rash, and the rash faded completely 3 months after drug withdrawal.

DISCUSSION

Up to 62% and 15% of patients treated with enalapril and captopril, respectively, were reported to develop a rash during the first few weeks of treatment. (1). Maculopapular, urticarial (2), pityriasis rosea-like (3), erythroderma (4), psoriasisform (5), lupus erythematosus-like (6) and pemphigus (7) have all been reported with captopril.

Two types of lichenoid eruptions have been described with captopril with different clinical and histological features (8). The first type of lichenoid eruption was preceded by a pityriasis rosea-like rash and was reported in four patients taking low doses of captopril (12.5–100 mg daily) (8, 9), and the rash evolved to leave hyperpigmented macules in two patients and small lichenoid papules in the other two patients before clearing after 1–2 weeks of drug withdrawal. The second type of lichenoid eruption occurred without any preceding rash and consisted of large lichenoid flat-topped papules which coalesced to form plaques. This type of rash was found in three patients taking large doses of captopril (100–450 mg daily), and the rash took 3–6 months to fade completely. The oral cavity was spared in all seven patients described. Our patient had similar clinical and histological features to the second type of lichenoid eruptions but differed in that she was taking a much lower dose of captopril comparatively (25 mg daily). The pathogenesis of captopril-induced lichenoid eruption is not well understood, though the presence of the active sulphurhydryl groups of captopril have been suggested to play an important role in the cell-mediated immunological reactions which lead to the development of the rash (10, 11). Our patient required captopril and benefited from using enalapril though cross sensitivity between these two drugs have been reported (12).

REFERENCES